



Ref. No.: EIKO/BSE/2022-23/41

Dated: 31.01.2023

To,
Corporate Services Department,
BSE Limited, P J Towers,
1st Floor, Dalal Street,
Fort, Mumbai - 400001

Sub: Outcome of the Board Meeting held today i.e. on 31st January, 2023

Ref: Eiko Lifesciences Limited

BSE Scrip Code: EIKO 540204

Dear Sir,

Pursuant to Reg. 30, 33 and other applicable regulations of the SEBI (LODR) Regulations, 2015, the Board of Directors of the Company, at their meeting held today i.e., on January 31, 2023 considered, approved, and taken on record the following:

1. To Increase Authorized Share Capital of the Company from the present ₹10,00,00,000/- (Rupees Ten Crore only) divided into 1,00,00,000 (One Crore) Equity Shares having face value of ₹10/- each to ₹14,00,00,000 (Rupees Fourteen Crore Only) divided into 1,40,00,000 (One Crore Forty Lakhs) Equity Shares having face value of ₹10/- each share and the consequential amendment in Clause V of the Memorandum of Association of the Company.
2. The Board has approved the fund raising and issuance of fully paid equity shares of the company for an amount not exceeding ₹25 Crores (Rupees Twenty Five Crores Only) by way of a right issue to the eligible equity shareholders of the company as on the record date (to be determined and informed subsequently), in accordance with applicable laws, including the Securities Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, subject to such approvals, as may be required under the applicable laws ("Right Issue"). For the purpose of giving effect to the Right issue, the detailed terms in relation to the Right issue, including but not limiting to the issue price, issue size, rights entitlement ratio, record date, timing and terms of payment will be determined in due course.

Further the Board has constituted and authorized 'Rights Issue Committee' to decide detailed terms and conditions of the Issue, including but not limiting to deciding the payment modalities/schedule thereof, record date, timings, appointment of intermediaries and legal counsel, if required, other terms and conditions, all other related matters, etc.



The details as required under SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, with respect to the Right issue are enclosed as **Annexure A**:

3. To seek requisite members approval for increase in authorised Share Capital of the Company and consequential amendment in Clause V of the Memorandum of Association of the Company, by way of passing resolutions through Postal Ballot. Detailed calendar of events for Postal Ballot will be shared in due course.
4. Appointment of M/s. Shravan Gupta and Associates, Practicing Company Secretary as a Scrutinizer for the purpose of conducting Postal Ballot and E voting in fair and transparent manner.

The meeting of the Board of Directors commenced at 4:00 p.m. and concluded at 5:10 p.m.

Further, with reference to our letter dated January 25, 2023, please note the trading window for dealing in the securities of the Company by the Insiders, as defined under the SEBI (Prohibition of Insider Trading) Regulations, 2015 shall re-open from Friday, February 03, 2023.

Please take the same on your records.

Thanking you.

For **EIKO LIFESCIENCES LIMITED**

Avi Mundecha
Company Secretary
ACS-65529

Encl.: As above.



Annexure A

The Disclosure pursuant to Regulation 30 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 with respect to Right Issue

Sr. No	Particulars	Details
1.	Type of securities proposed to be issued	Equity Share of the face value of ₹10 each of the Company.
2.	Type of issuance (further public offering, rights issue, depository receipts (ADR /GDR), qualified institutions placement, preferential allotment etc.)	Right issue to the existing shareholders
3.	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately);	Number of Equity Share and, in such ratio, as may be decided by the Board of Directors/Rights Issue Committee for an Amount not exceeding ₹25 Crore (Rupees Twenty-Five Crores Only)
4.	Any cancellation or termination of proposal for issuance of Securities including reasons thereof.	NA